Regular ArticleImplication of Malignancy and Prognosis of p27kip1, Cyclin E, and Cdk2 Expression in Epithelial Ovarian Tumors☆
References (40)
- et al.
The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer
Gynecol Oncol
(1995) G1 phase progression: cycling on cue
Cell
(1994)The retinoblastoma protein and cell cycle control
Cell
(1995)- et al.
Overexpression of cyclin D1 in epithelial ovarian cancers
Gynecol Oncol
(1997) - et al.
Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors
Am J Pathol
(1999) - et al.
The concurrent expression of p27kip1 and cyclin D1 in epithelial ovarian tumors
Gynecol Oncol
(1999) - et al.
Inverse expression of cdk4 and p16 in epithelial ovarian tumors
Gynecol Oncol
(2000) - et al.
Low p27 expression predicts poor disease-free survival in patients with prostate cancer
J Urol
(1998) - et al.
The epidemiology of ovarian cancer
J Cell Biochem Suppl
(1995) - et al.
Management of early ovarian cancer
Semin Oncol
(1998)
Chemotherapy of advanced ovarian cancer
Semin Oncol
Cell cycle and cancer: critical events at the G1 restriction point
Crit Rev Oncogen
Cancer cell cycle
Science
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution
Genes Dev
Inhibitors of mammalian G1 cyclin dependent kinases
Genes Dev
Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors
Int J Cancer
Expression of cyclin D1 correlates with malignancy in human ovarian tumours
Br J Cancer
Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas
Int J Cancer
Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression
Int J Cancer
Cited by (89)
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients-A study of the OVCAD consortium
2014, European Journal of CancerCitation Excerpt :Taken together, our results indicate that amplification of CCNE1 and – to a less content – CCNE2 is a frequent event in EOC, but not the main cause of the gene regulation of both cyclins. CCNE2 seems to be the active gene in the ovary, whereas CCNE1 seems to be highly expressed in placenta and testis [14] and overexpressed in many cancer tissues, including breast and ovarian cancer [9,10,41,42]. Evidence for prognostic relevance of cyclin E (protein) expression in EOC is ambiguous, some authors found an independent negative impact of high cyclin E expression on overall survival [9,11,12], others (using 493 EOC tissues) reported no independent impact on OS [40].
Could cannabinoids provide a new hope for ovarian cancer patients?
2023, Pharmacology Research and PerspectivesSCUBE3 downregulation modulates hepatocellular carcinoma by inhibiting CCNE1 via TGFβ/PI3K/AKT/GSK3β pathway
2022, Cancer Cell InternationalUp-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin
2021, Journal of Ovarian Research
- ☆
This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, and Science of Japan.
- 2
To whom correspondence should be addressed at Department of Physiology, Kagawa Medical University, 1750-1 Ikenobe, Miki-Cho, Kida-Gun, Kagawa 761-0793, Japan. Fax: +81-87-891-2096. E-mail: [email protected].